Ltd. Kck Sells 4,031 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 4,031 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $6.54, for a total value of $26,362.74. Following the completion of the sale, the insider now owns 5,521,874 shares of the company’s stock, valued at $36,113,055.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The shares were sold at an average price of $6.57, for a total value of $45,333.00.
• On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The stock was sold at an average price of $6.35, for a total value of $16,332.20.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The stock was sold at an average price of $6.10, for a total value of $19,050.30.
• On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The stock was sold at an average price of $6.66, for a total transaction of $32,700.60.
• On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The stock was sold at an average price of $6.97, for a total transaction of $23,126.46.

NeuroPace Price Performance

Shares of NASDAQ NPCE opened at $6.47 on Friday. The firm has a market capitalization of $186.13 million, a P/E ratio of -5.44 and a beta of 1.78. The firm’s 50-day moving average price is $7.05 and its 200-day moving average price is $8.38. The company has a current ratio of 6.37, a quick ratio of 5.47 and a debt-to-equity ratio of 5.97. NeuroPace, Inc. has a 1-year low of $5.73 and a 1-year high of $18.15.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. The business had revenue of $19.26 million for the quarter, compared to the consensus estimate of $18.30 million. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The firm’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.36) EPS. Equities research analysts anticipate that NeuroPace, Inc. will post -1.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NeuroPace

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in NeuroPace by 18.3% in the 1st quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock valued at $6,450,000 after purchasing an additional 75,512 shares during the period. Acadian Asset Management LLC bought a new position in shares of NeuroPace in the first quarter valued at $621,000. Hillsdale Investment Management Inc. acquired a new position in shares of NeuroPace during the first quarter valued at about $155,000. Bank of New York Mellon Corp bought a new stake in shares of NeuroPace during the second quarter worth about $257,000. Finally, Financial Advocates Investment Management raised its holdings in shares of NeuroPace by 50.0% in the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock worth $113,000 after acquiring an additional 5,000 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on NPCE shares. Wells Fargo & Company dropped their target price on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. Morgan Stanley dropped their price objective on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $18.00 target price on shares of NeuroPace in a research report on Wednesday, August 14th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.00.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.